American Century Companies’s Enanta Pharmaceuticals ENTA Stock Holding History

American Century Companies’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,764	Closed	-$532K	–	2860
2025 Q4	$532K	Sell	33,764 -14,807	-30%	-$188K	﹤0.01%	2502
2025 Q3	$581K	Buy	48,571 +7,791	+19%	+$62.3K	﹤0.01%	2468
2025 Q2	$308K	Buy	40,780 +776	+2%	+$4.67K	﹤0.01%	2658
2025 Q1	$221K	Buy	40,004 +3,042	+8%	+$18.8K	﹤0.01%	2741
2024 Q4	$213K	Buy	36,962 +3,501	+10%	+$33.6K	﹤0.01%	2773
2024 Q3	$347K	Buy	33,461 +5,569	+20%	+$72.8K	﹤0.01%	2589
2024 Q2	$362K	Buy	27,892 +7,287	+35%	+$98.4K	﹤0.01%	2558
2024 Q1	$360K	Buy	20,605 +9,975	+94%	+$132K	﹤0.01%	2566
2023 Q4	$100K	Buy	+10,630	New	+$99K	﹤0.01%	2813
2020 Q2	–	Sell	-18,333	Closed	-$943K	–	1749
2020 Q1	$943K	Buy	18,333 +93	+0.5%	+$4.96K	﹤0.01%	999
2019 Q4	$1.13M	Sell	18,240 -27,264	-60%	-$1.69M	﹤0.01%	1078
2019 Q3	$2.73M	Buy	+45,504	New	+$3.38M	﹤0.01%	924
2018 Q4	–	Sell	-37,606	Closed	-$3.21M	–	1263
2018 Q3	$3.21M	Buy	37,606 +5,178	+16%	+$519K	﹤0.01%	943
2018 Q2	$3.76M	Buy	+32,428	New	+$3.24M	﹤0.01%	906
2016 Q1	–	Sell	-79,158	Closed	-$2.61M	–	1316
2015 Q4	$2.61M	Buy	79,158 +234	+0.3%	+$7.63K	﹤0.01%	981
2015 Q3	$2.85M	Buy	78,924 +51,124	+184%	+$2.2M	﹤0.01%	969
2015 Q2	$1.21M	Buy	+27,800	New	+$1.08M	﹤0.01%	1119

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

American Century Companies's ENTA Position: Q1 2026 in Review

American Century Companies sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 33,764 shares — an estimated $532K sold.

American Century Companies first reported a position in ENTA in Q2 2015 and held it in 17 quarters. The position peaked at $3.76M in Q2 2018. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

American Century Companies reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
American Century Companies sold 33,764 Enanta Pharmaceuticals shares in Q1 2026, an estimated $532K.
American Century Companies first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 17 quarters.
American Century Companies's Enanta Pharmaceuticals position peaked at $3.76M in Q2 2018.
133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.